Overview

A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical study is to evaluate the safety and tolerability (side effects) and pharmacokinetics (drug levels in the body) of 80mg neflamapimod given twice daily in patients with dementia with Lewy bodies.
Phase:
PHASE2
Details
Lead Sponsor:
EIP Pharma Inc
Collaborator:
CervoMed, Inc
Treatments:
VX-745